Search company, investor...
IMEDOS company logo


Founded Year



Other Investors | Alive


Headquarters Location

Am Naßtal 4



Missing: IMEDOS's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: IMEDOS's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Latest IMEDOS News

Imedos technology for static vessel analysis: Targeted identification of high-risk individuals for severe progressions of COVID-19

Jul 27, 2020

) Despite initial easing of lockdowns and restrictions related to the Corona pandemic, it remains central to identify high-risk individuals in order to protect them from both an infection with the virus as well as possible severe progressions of COVID-19. According to the Robert-Koch-Institute, these risk groups include people with underlying diseases, such as cardiovascular diseases, heart diseases, diabetes, hypertension and vascular diseases. The systems for static vessel analysis from Imedos Systems GmbH , a leading manufacturer of medical devices, provide important parameters about the individual risk of patients including information on the occurrence of cardiovascular diseases and events (e.g. heart attack and stroke). Cardiovascular diseases, such as heart failure and high blood pressure, lead to changes in the condition of the smallest vessels of the human body at a very early stage. These changes can be detected via the retina of the eyes which represents a unique mirror of the entire body. The microcirculation of the retina can be used to draw conclusions about the individual vascular condition, vascular functions and vascular risk factors of each patient. And, as a unique and special characteristic, the individual probability of cardiovascular diseases can be determined even before first symptoms of the disease appear. An important fact in connection with the current Corona pandemic, as patients who contract the SARS-CoV-2 virus are often unaware of their pre-existing conditions and the associated risk. Designed for use in research and clinical applications, Imedos' systems for static vessel analysis facilitate the determination of vascular conditions. The examination is carried out on the basis of individual images of the vascular network of the retina. Via a non-invasive and contactless look into the patients’ eye both the diameters of the retinal arteries and veins as well as important static vessel parameters are determined in a quick and precise manner. "Tight arteries and wide veins are very good and proven predictors for cardiovascular diseases and events," explains Dr. Walthard Vilser, Managing Director of Imedos Systems GmbH, about the potential of the technology. "Preventive medicine is Imedos' central concern. Persons who are particularly at risk of coming into contact with COVID-19, such as healthcare professionals, could therefore use the method of static vessel analysis to determine their affiliation with the risk group and, if necessary, better protect themselves from any infection." List of references: Imedos Systems GmbH Imedos specializes in retinal microcirculation and develops medical device systems for microvascular research and functional diagnostics. Through decades of research and development, the company has established itself as a highly innovative manufacturer of analytical systems and software. These are used not only by ophthalmologists but also by specialists from other medical disciplines worldwide. The retina of the eyes acts as a unique mirror of the entire human body. Thus, the retinal microcirculation that takes place here can be used to draw conclusions about the individual vascular condition, vascular functions and vascular risk factors. Early detection of these vascular risks facilitates the prevention of cardio- and cerebrovascular diseases in a targeted manner. This opens up a wide range of applications, far beyond ophthalmology. Das könnte Sie auch interessieren 27.05.2020

IMEDOS Frequently Asked Questions (FAQ)

  • When was IMEDOS founded?

    IMEDOS was founded in 1996.

  • What is IMEDOS's latest funding round?

    IMEDOS's latest funding round is Other Investors.

  • Who are the investors of IMEDOS?

    Investors of IMEDOS include bm-t beteiligungsmanagement thuringen, AVIDA Equity Partners, High Tech Beteiligungen & KG and High Tech Private Equity.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.